Coherus Oncology
CHRS
161 hedge funds and large institutions have $371M invested in Coherus Oncology in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 71 increasing their positions, 42 reducing their positions, and 29 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 42
7% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 29
1% less funds holding
Funds holding: 163 → 161 (-2)
6.61% less ownership
Funds ownership: 98.52% → 91.91% (-6.6%)
30% less call options, than puts
Call options by funds: $665K | Put options by funds: $954K
31% less capital invested
Capital invested by funds: $536M → $371M (-$165M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$26.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.7M |
| 3 |
Morgan Stanley
New York
|
+$14.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$10.1M |
| 5 |
BlackRock
New York
|
+$8.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$35.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$20.9M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$3.76M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.67M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.55M |
CHRS Hedge Fund Activity: Q2 2023 in Review
161 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2023, worth a combined $371M — down 31% from $536M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CHRS and 27 opened new positions — a net loss of 2 holders — while 42 trimmed existing stakes and 71 added.
The largest buyer was Citadel Advisors, adding an estimated $26.4M. The largest seller was AllianceBernstein, cutting an estimated $35.1M.
- 161 institutional investors held Coherus Oncology (CHRS) as of Q2 2023, down from 163 in Q1 2023.
- Funds reported $371M of Coherus Oncology stock for Q2 2023, down 31% quarter-over-quarter.
- 27 funds opened new Coherus Oncology positions in Q2 2023 and 29 closed out, a net change of -2 holders.
- The largest Coherus Oncology buyer in Q2 2023 was Citadel Advisors, an estimated $26.4M added.
- The largest Coherus Oncology seller in Q2 2023 was AllianceBernstein, an estimated $35.1M sold.
Based on aggregated 13F filings for Q2 2023.